-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bomedemstat Tosylate in Myelofibrosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bomedemstat Tosylate in Myelofibrosis Drug Details: IMG-7289 is under development for the treatment of acute...
-
Product Insights
Tourette Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Tourette Syndrome - Drugs In Development, 2023’, provides an overview of the Tourette Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tourette Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Actinic (Solar) Keratosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Actinic (Solar) Keratosis - Drugs In Development, 2023’, provides an overview of the Actinic (Solar) Keratosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Chemotherapy Induced Neutropenia – Drugs In Development, 2023
Global Markets Direct’s, ‘Chemotherapy Induced Neutropenia - Drugs In Development, 2023’, provides an overview of the Chemotherapy Induced Neutropenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2023’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Leukocyte Disorders (White Blood Cell Disorders) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leukocyte Disorders (White Blood Cell Disorders) - Drugs In Development, 2023’, provides an overview of the Leukocyte Disorders (White Blood Cell Disorders) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leukocyte Disorders (White Blood Cell Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Nonmelanomatous Skin Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Nonmelanomatous Skin Cancer - Drugs In Development, 2023’, provides an overview of the Nonmelanomatous Skin Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nonmelanomatous Skin Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Human Papillomavirus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Human Papillomavirus Infections - Drugs In Development, 2023’, provides an overview of the Human Papillomavirus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
Eastern Europe Foodservice Market Size and Trends by Profit and Cost Sector Channels, Players and Forecast to 2027
Eastern Europe Foodservice Market Report Overview The Eastern Europe foodservice profit sector recorded sales of $80.1 billion in 2022 and is forecast to record a strong CAGR of over 20% during 2022-2027. The Eastern European foodservice industry is witnessing a surge in the adoption of vegan and plant-based diets by consumers. Thus, plant-based menus, featuring innovative alternatives to traditional dishes are becoming increasingly popular. Additionally, restaurants and cafes across the region are increasingly adopting eco-friendly practices to minimize their environmental...
-
Product Insights
Sibel Wind Farm
Sibel Wind Farm is an Onshore Wind project located in Manisa, Turkey. The project is owned by Boydak Enerji Uretim ve Tic AS and was developed by Boydak Enerji Uretim ve Tic AS; Sibelres Elektrik Uretim AS. The project came online in 2020. Empower your strategies with our Sibel Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business...